Literature DB >> 9933172

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

J E Schmitz1, M J Kuroda, S Santra, V G Sasseville, M A Simon, M A Lifton, P Racz, K Tenner-Racz, M Dalesandro, B J Scallon, J Ghrayeb, M A Forman, D C Montefiori, E P Rieber, N L Letvin, K A Reimann.   

Abstract

Clinical evidence suggests that cellular immunity is involved in controlling human immunodeficiency virus-1 (HIV-1) replication. An animal model of acquired immune deficiency syndrome (AIDS), the simian immunodeficiency virus (SIV)-infected rhesus monkey, was used to show that virus replication is not controlled in monkeys depleted of CD8+ lymphocytes during primary SIV infection. Eliminating CD8+ lymphocytes from monkeys during chronic SIV infection resulted in a rapid and marked increase in viremia that was again suppressed coincident with the reappearance of SIV-specific CD8+ T cells. These results confirm the importance of cell-mediated immunity in controlling HIV-1 infection and support the exploration of vaccination approaches for preventing infection that will elicit these immune responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933172     DOI: 10.1126/science.283.5403.857

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  948 in total

1.  Specific therapy regimes could lead to long-term immunological control of HIV.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

2.  The challenge of immune control of immunodeficiency virus.

Authors:  D Richman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Authors:  M Dalod; M Dupuis; J C Deschemin; C Goujard; C Deveau; L Meyer; N Ngo; C Rouzioux; J G Guillet; J F Delfraissy; M Sinet; A Venet
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

4.  DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.

Authors:  S Cherpelis; I Shrivastava; A Gettie; X Jin; D D Ho; S W Barnett; L Stamatatos
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  The simian immunodeficiency virus envelope glycoprotein contains two epitopes presented by the Mamu-A*01 class I molecule.

Authors:  M Furchner; A L Erickson; T Allen; D I Watkins; A Sette; P R Johnson; C M Walker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

6.  HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.

Authors:  P J Goulder; Y Tang; S I Pelton; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

7.  Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.

Authors:  P J Goulder; C Brander; K Annamalai; N Mngqundaniso; U Govender; Y Tang; S He; K E Hartman; C A O'Callaghan; G S Ogg; M A Altfeld; E S Rosenberg; H Cao; S A Kalams; M Hammond; M Bunce; S I Pelton; S A Burchett; K McIntosh; H M Coovadia; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 8.  Proving HIV-1 immunity: new tools offer new opportunities.

Authors:  L J Picker
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

9.  HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death.

Authors:  S J Brodie; B K Patterson; D A Lewinsohn; K Diem; D Spach; P D Greenberg; S R Riddell; L Corey
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

10.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.